Cipla receives USFDA nod to market Lanreotide injection in US

20 Dec 2021 Evaluate

Cipla has received approval from the US Food and Drug Administration (USFDA) to market the Lanreotide injection in the American market. The Lanreotide injection is used for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors. 

This approval is a significant step for its US business and is in line with its aspiration to continue growth in its complex product pipeline and address unmet patient needs.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1328.25 15.40 (1.17%)
28-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.15
Dr. Reddys Lab 1224.30
Cipla 1328.25
Zydus Lifesciences 896.60
Lupin 2121.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×